Mtz Clinical Research Powered By Pratia

Warsaw 95 trials 45 recruiting

95 Registered trials

45 Currently recruiting

Organisation

Mtz Clinical Research Powered By Pratia

Location

Warsaw, Poland

Identifier

ORG-100037261

Address

Ul. Gładka 22, 02-172, Poland

Departments

-
#40699: N/A
Badania Kliniczne
Cardiology
Clinical Unit
Dermatology
Gynaecology
Hematology
Mtz Clinical Research Powered By Pratia
MTZ Clinical Research powered by Pratia, Warszawa
n/a
N/D
NA
NA/ND
ND
Neurology
Oncology
Phase I unit
Private Practice
Psychiatry
Site unit

Clinical trials at this site (95)

Search interface

Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended

2024-514559-13-00 Focal Epilepsy 10 2024-11-26
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas… Ended

2023-509947-29-00 Anemia in patients with very low, low or intermediate r 4 2024-07-18
A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure… Ended

2023-507640-36-00 Resistant hypertension (rHTN) defined as blood pressure 5 2024-04-29
A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended

2023-505499-32-00 Uncontrolled hypertension (uTHN) defined as blood press 5 2024-03-08
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended

2023-505910-10-00 Relapsed or Refractory High-Risk Myelodysplastic Syndro 4 2024-01-23
A bioequivalence vasoconstriction study comparing two clobetasol propionate 0.5 mg/g ointments after skin application in healthy adult human… Ended

2023-504707-87-00 Localized, therapy-resistant inflammatory skin diseases 2 2023-11-20
UNITAS Ended

2022-502483-21-00 Insomnia disorder 4 2023-07-28
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Migraine attacks with or without aura 6 2023-03-14
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended

2023-503615-14-00 Relapsed or Refractory Classical Hodgkin Lymphoma 4 2022-09-29
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
Eptinezumab as Preventive Treatment of Migraine in Adults with Migraine Ended

2023-510183-12-00 Chronic migraine 5 2021-07-05
Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus Ended

2022-502444-13-00 Systemic Lupus Erythematosus 4 2019-05-28
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su… Ended

2022-501971-24-00 Adjuvant treatment of HCC 5 2019-05-20
A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended

2023-508955-37-00 Moderate to severe atopic dermatitis 5 2018-10-10